Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Amgen

Sanofi

Medicines

Regeneron Pharmaceuticals

Swiss drugmaker Novartis  is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co  as it challenges cardiovascular medicines from Amgen Inc , Sanofi  and Regeneron Pharmaceuticals.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Novartis will buy The Medicines Company for $9.7 billion, adding a promising cholesterol treatment to its wheelhouse, the Swiss pharma giant announced Sunday.
The post Novartis Announces $9.7 Billion Takeover Of The Medicines Company appeared first on Investor's Business Daily.

Novartis Announces $9.7 Billion Takeover Of The Medicines Company

Novartis has agreed to pay $85 a share for Medicines Company in a deal that could be reached this weekend, according to The Wall Street Journal.

Novartis reportedly nears deal to buy cholesterol drugmaker Medicines Company for $7 billion

Swiss drugmaker Novartis AG  is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co  for about $7 billion, the Wall Street Journal reported on Saturday.

Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJ

Global Blood Therapeutics

Transformative new therapies are changing the treatment landscape for patients with sickle cell disease, and savvy investors can benefit in this David-versus-Goliath scenario. Which one is the better buy today?

Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell

Medicines Co. (NASDAQ: MDCO) shares shot up on Tuesday after it was reported that Novartis A.G.

Will Medicines Co Be the Next Target of Novartis?

Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.

Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease

Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.

FDA Approves Crizanlizumab: Here Is A New Drug For Sickle Cell Disease

AbbVie

Biogen

Innoviva

Mylan

Theravance Biopharma

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline        

Veeva Systems

These three companies have a lot going right for them.

3 Top Healthcare Stocks to Buy Right Now.

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

Novartis' Generics Unit to Buy Aspen's Japanese Operations

AstraZeneca

Portola Pharmaceuticals

These three healthcare companies have a lot of good signs going for them.

3 'Top Healthcare' Stocks to Buy Now

Second Zolgensma Data Snafu For Novartis Not Such A Big Deal

Novartis stock dipped Wednesday after the Food and Drug Administration placed a clinical hold on a study of the world's most expensive gene therapy, a drug called Zolgensma.
The post Novartis Dips As The World's Most Costly Drug Faces Safety Concerns appeared first on Investor's Business Daily.

Novartis Dips As The World's Most Costly Drug Faces Safety Concerns

Novartis received FDA approval for Beovu to treat patients with wet age-related macular degeneration.

With FDA Approval In Hand, Novartis Is Primed For Competitive Wet AMD Market

Is  (NVS) Outperforming Other Medical Stocks This Year?

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

New breast cancer trial results could prove to be a major catalyst for the stock.

Is Novartis a Buy?

Novartis obtains positive results in phase 1/2 study using Zolgensma to treat patients with SMA who are between the ages of 2 and 5.

Novartis Looks To Expand Zolgensma's Marketing Reach With Latest Positive Data

Novartis AG (NVS) CEO Vasant Narasimhan - CEO on Q3 2019 Results - Earnings Call Transcript

Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.

Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y

Novartis AG raised its earnings forecast for the third time this year as new drugs including gene therapy Zolgensma got off to a strong start. The Swiss drugmaker also lifted.

Novartis Boosts Forecast Again As New Gene Therapy Shines

Novartis earnings and sales topped Q3 views, with the Swiss drug giant also raising some full-year guidance. Novartis stock fell slightly early Tuesday.

Novartis Earnings Top; Swiss Drug Giant Edges Lower

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

Novartis announced positive results in its phase 3 study using Kisqali along with endocrine therapy to treat women with postmenopausal advanced breast cancer.

News for Novartis Stock (NVS)